UniQure climbs after trial results for genetic disorder treatment
19/12/2023 14:02
** Shares of gene therapy developer uniQure QURE.O rise
~1.6% to $8.11 premarket
** Co says its early to mid-stage trial testing AMT-130
showed evidence of preserved neurological function in patients
with Huntington's disease (HD)
** Brokerage Stifel says that the trial results look
favorable and could reinvigorate interest into the stock heading
into 2024
** HD is an inherited disorder that causes nerve cells in
parts of the brain to gradually break down and die
** Up to last close, stock down 64.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal